Breast Cancer Recurrence Test Gets FDA Nod
(American C


American Cancer Society - The US Food and Drug Administration has approved
MammaPrint, a new genetic test that can help predict whether a woman's
early stage breast
cancer is likely to come back after initial treatment. The test is one
of several that could help breast cancer patients and their doctors make
decisions about how aggressively to treat the disease.